Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.46 |
| ▸ | ITGAL | P20701 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16401 | 1.00 | ECE1 (0.50) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL7184807 | 1.00 | ECE1 (0.50) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL5613494 | 0.93 | ECE1 (0.53) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL7022643 | 0.93 | ECE1 (0.53) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL618873 | 0.93 | ECE1 (0.53) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL546997 | 0.93 | ECE1 (0.53) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL9015921 | 0.87 | MEN1 (0.44) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL151539 | 0.87 | MEN1 (0.44) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL15442513 | 0.87 | ECE1 (0.44) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL8470054 | 0.87 | ECE1 (0.44) | ECE1MEN1KMT2AITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4337270-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-03-20 | — | — | EP | disclosed |
| CN-117320759-A | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | 慕尼黑工业大学 | 2023-12-29 | — | — | CN | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ECE1 1629/4885MEN1 1217/4885KMT2A 1801/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ECE1 997/4885MEN1 1147/4885KMT2A 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.